Tag Archives: Early Detection of Preclinical Disease

More on the NHS Long Term Plan (DHSC / NHS England / BBC News / NAO / King’s Fund)

Posted on January 9, 2019 by Dementia and Elderly Care News

Summary The NHS Long Term Plan was released earlier this week. The plan is backed by the commitment of an extra £20.5 billion funding for the NHS per year. “The 10-year plan includes measures to prevent 150,000 heart attacks, strokes … Continue reading →

Prevention: Central to the NHS Long Term Plan (BBC News / NHS Egland)

Posted on January 6, 2019 by Dementia and Elderly Care News

Summary Early announcements concerning the NHS Long Term Plan, previously billed as the “NHS Ten Year Plan”, indicate an even greater emphasis on the prevention agenda. This will involve, among other related schemes, the provision for problem drinkers and smokers … Continue reading →

Posted in Acute Hospitals, BBC News, Commissioning, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, Management of Condition, Mental Health, National, NHS, NHS England, Non-Pharmacological Treatments, Patient Care Pathway, Patient Information, Person-Centred Care, Personalisation, Quick Insights, Royal College of Physicians, Standards, Statistics, UK, Universal Interest | Tagged Access to Personal Health Records Online, Access to Primary Care, Ageing Population, Alcohol Abuse, Alcohol and Drug Consumption, Alcohol Care Teams, Alcohol Consumption, Alcohol Drugs and Tobacco, Alcohol Misuse, Alcohol or Tobacco Withdrawal, Alcohol-Related Activity in Hospitals, Alcohol-Related Admissions to Hospital, Alcohol-Related Burden on the NHS, Alcohol-Related Harm, BBC Health News, Benefits of Detection and Early Intervention, Benefits of Early Detection, Cancer Survival, Cancer Survival Rates in England, Childhood Obesity, Choice and Control, Choice and Control Over Decisions, Community Resilience, Community-Based Care, Community-Based Interventions, Community-Based Services, Community-Based Support, Control and Independence, Deborah Arnott: Chief Executive of ASH (Health Charity), Dementia Risk Reduction and Prevention, Diabetes, Diabetes Prevention, Diet, Diet and Exercise, Diet-Related Ill Health, Dietary Risk Factors, Digital Health Innovations, Digital Innovation, Digital Innovations in Health, Digital Service Transformation, Digital Services, Digital Services for Patients, Digital Technology and Innovation, Duncan Selbie: Chief Executive of Public Health England, Early Detection of Disease, Early Detection of Preclinical Disease, Economic Sustainability, Efficiencies and Productivity Gains, Efficiency and Effectiveness, Efficiency Opportunities, Efficiency Savings, Electronic Care Record (ECR), Electronic Health Records, Electronic Health Records (EHRs), Electronic Patient Record (EPR), Electronic Patient Record Systems, Health Information Technology, Health Innovation, Healthy Ageing, Healthy Behaviours, Healthy Communities, Healthy Lifestyles, Hospital Stays for Alcohol-Related Harm (Adults’ Health and Lifestyle), Information Technology, Informed Choices About Health and Social Care, Informed Decision-Making, Integrated Prevention Approaches, Lifestyle Risk Factors, Long-Term Funding Settlement for NHS, Maternal Health and Wellbeing, Maternal Mental Health, Maternity Services, Matt Hancock: Secretary of State for Health and Social Care, National Childhood Obesity Strategy, NHS Long Term Plan (2019), NHS Long-Term Plan, NHS Sustainability, NHS Ten Year Plan, NHS Workforce, Optimising Benefits of Digital Technology, Optimising Patient Outcomes Using Digital Technology, Optimising Use of Digital Technology, Personal Budgets (PBs), Personal Budgets for Older People, Preventative Care, Preventative Services, Preventing Avoidable Emergency Admissions, Prevention, Prevention Agenda, Prevention Agenda Linking Dementia and Other Non-Communicable Diseases, Prevention and Self Care, Prevention Programmes, Preventive Care, Preventive Services, Prime Minster: Rt Hon Theresa May MP, Professor Andrew Goddard: President of Royal College of Physicians, Recruitment, Recruitment and Retention, Reducing Alcohol-Related Harm, Reducing Unnecessary Admissions, Reducing Unscheduled Admissions, Reducing Waste in the NHS, Royal College of Physicians (RCP), Rt Hon Matt Hancock MP, Rt Hon Theresa May MP (Prime Minster), Self-Care, Self-Determination, Self-Management Support, Service User Involvement, Simon Stevens: Chief Executive of NHS England, Smoking, Smoking Cessation, Specialist Alcohol Care Teams Trials, Support for Self-Care, Supporting Healthy Lifestyles, Sustainability, Theresa May's Mental Health Reforms, Tobacco, Tobacco Advisory Group: Royal College of Physicians, Tobacco Consumption, Tobacco Dependency, Tobacco Smoking, Transformational Technologies, Transformative Health Technology, Transformative Technology, Treating Patients Closer to Home, UK Cancer Survival Rates, Unhealthy Lifestyles, Use of Technology to Predict Illnesses and Target Advice, Workforce Competencies, Workforce Development, Workforce Issues | Leave a comment

Investigations Into the Early Signs, Symptoms and Family Experiences of Alzheimer’s Disease (BMJ Open / International Psychogeriatrics)

Posted on May 23, 2018 by Dementia and Elderly Care News

Summary A literature review analyses the sequence / timing of the early signs and symptoms of Alzheimer’s Disease. The authors distinguish between the early signs of late-onset Alzheimer’s Disease (LOAD) and those of early-onset Alzheimer’s Disease (EOAD). Full Text Link … Continue reading →

Posted in Community Care, Depression, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), International, Mental Health, Models of Dementia Care, Quick Insights, Systematic Reviews, UK, Universal Interest | Tagged Aberrant Motor Behaviour, Acalculia, Agitation, Alexia, Anomia, Anosognosia, Anxiety, Apathy, Australia, BMJ Open, BMJ Publishing Group Ltd, Box Hill Hospital (Victoria), Cognitive Impairment, Conversion to Dementia From Prodromal Disease, Disinhibition, Early Detection of Preclinical Disease, Early Signs and Symptoms of Alzheimer's Disease, Early-Onset Alzheimer’s Disease (EOAD), Early-Onset Dementia, Eastern Cognitive Disorders Clinic: Box Hill Hospital, Experiences, Experiences of the Transition to Dementia, Family and Caregiver Experiences, Family Members' Experiences of Pre-Diagnostic Phase of Dementia, Hallucination, Initial Onset and Diagnosis, Institute for Health Research: University of Bedfordshire, International Psychogeriatrics, Irritability, Late Onset Dementia, Late-Onset Alzheimer's Disease, Late-Onset Alzheimer's Disease (LOAD), Melbourne School of Psychological Sciences: University of Melbourne, Neuroscience Department: Box Hill Hospital, Olfactory Disturbances, Patient and Carer Experiences, Patient Experiences, Pre-Diagnostic Phase of Dementia, Preclinical Alzheimer's Disease, Preclinical Indicators in Alzheimer's Disease, Preclinical Phase of Dementia, Prodromal Alzheimer's Disease, School of Life Sciences: University of Hull, Signs and Symptoms of Alzheimer's Disease, University of Bedfordshire, University of Hull, University of Melbourne, Weight Loss, Young Onset Dementia (YOD), Young-Onset Dementia | Leave a comment

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

Posted on June 28, 2017 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study aims to discover new ways of diagnosing dementia, ideally decades before the symptoms become apparent in order to give future drug treatments the best chance of working. The Deep and Frequent Phenotyping Study … Continue reading →

Posted in Alzheimer's Society, BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Ageing Population, Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Applications of Big Data, BBC Radio, BBC Radio 4, BBC's World At One Programme, Big Data Analytics, Big Data Funding and Research, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Neuropsychological Test Automated Battery (CANTAB), Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Deep and Frequent Phenotyping Study (DFP), Deep and Frequent Phenotyping; Combinatorial Biomarkers of Dementia, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, DFP Study Team, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Gait and Cognition, Gait Changes, Gateway to Research (GtR), Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, Join Dementia Research, Join Dementia Research: Clinical Trials Matchmaker Service, Join Dementia Research: Recruitment Onto Dementia Studies, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurobiology of Aging (Journal), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Open Data and Big Data, Ophthalmological Assessments, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, PharmaCog Consortium, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Clare Mackay: Imaging Neuroscience at the University of Oxford, Professor Lynn Rochester: Clinical Ageing Research Unit at Newcastle University, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Publicly-Funded UK Big Data Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Screening Tools for Amnestic Mild Cognitive Impairment (a-MCI), Surrogate Biomarkers of Neurodegeneration, Translational Research, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology) | Leave a comment

Developments in Dementia Research: From the Horses’ Mouths (NHS England / NIHR)

Posted on August 25, 2016 by Dementia and Elderly Care News

Summary Professor Alistair Burns (NHS England’s National Clinical Director for Dementia and Older Peoples’ Mental Health), and Professor Martin Rossor (NIHR National Director for Dementia Research), discuss current issues and new approaches in dementia research, touching briefly upon some of … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Models of Dementia Care, National, NHS England, NIHR, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged 100000 Genomes Project, A4 Study, Alistair Burns: Honorary Consultant Old Age Psychiatrist in the Manchester Mental Health and Social Care Trust (MMHSCT), Alistair Burns: NHS England’s National Clinical Director for Older People’s Mental Health, Alistair Burns: Professor of Old Age Psychiatry at University of Manchester, Alzheimer's Prevention Initiative, Alzheimer’s Disease Biomarkers, Alzheimer’s Prevention Initiative Study, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4 Study), APP and Presenilin, Asymptomatic Alzheimer’s Disease, Banner Alzheimer's Institute, Biomarkers, Chance Genetic Mutations, Colombia, Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, DIAN-TU Study, DIAN-TU Trial, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Genentech, Genomics, Genomics England, Genomics in the NHS, Genomics-Based Medicine, Global Outlook, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Medellin (Colombia), Monoclonal Antibodies, MRC Neurochemical Pharmacology Unit, Mutational Signatures, National Clinical Director for Dementia, National Institute for Health Research (NIHR), National Institutes of Health (NIH), National Institutes of Health (US), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, NIHR Clinical Research Network, NIHR Dementia Translational Research Collaboration, NIHR National Director for Dementia Research, NIHR Translational Research Collaboration, Overcoming Barriers, Participation in Research, Participation in Research Studies, Preclinical Alzheimer's Disease, Presenilin, Prodromal Alzheimer's Disease, Professor Alistair Burns, Professor Martin Rossor: Director of the NIHR Queen Square Dementia Biomedical Research Unit, Professor Martin Rossor: Former Director of the NIHR Dementia and Neurodegenerative Disease Research Network (DeNDRoN), Professor Martin Rossor: Former President of the Association of British Neurologists (2011-2013), Professor Martin Rossor: Honorary Consultant Neurologist at National Hospital for Neurology and Neurosurgery, Professor Martin Rossor: National Hospital (Queen Square), Professor Martin Rossor: NIHR National Director for Dementia Research, Professor Martin Rossor: UCL Institute of Neurology, Promisary Science, Reducing Downstream Effects of Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Solanezumab (Sola or Solab), Solanezumab: Humanised Monoclonal Antibody, Therapeutic Nihilism (Avoiding), Translational Research, UK Genomes Project: Genomics England, University of Southern California’s Alzheimer’s Therapeutic Research Institute, Washington University School of Medicine | Leave a comment

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

Posted on August 22, 2016 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer’s Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the … Continue reading →

Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Aridhia, AstraZeneca / MedImmune, Berry Consultants, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Cognition, Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Dr Rob Buckle: Director of Science Programmes at MRC, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Exprodo, Gait and Cognition, Gait Changes, Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, IXICO, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Ophthalmological Assessments, Optos, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Chris Whitty: Chief Scientific Adviser at Department of Health, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Sage Bionetworks, Surrogate Biomarkers of Neurodegeneration, Translational Research, TrialSpark, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology), West London Mental Health Trust / Imperial College London | 1 Comment

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

Posted on February 3, 2016 by Dementia and Elderly Care News

Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →

Tag Archives: Early Detection of Preclinical Disease

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites